An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

Abstract excerpt

Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in non-small cell lung cancer specimens from patients responding to anilinoquinazoline EGFR inhibitors. However, clinical resistance to EGFR inhibitor therapy is commonly observed. Previously, we showed that such resistance can be caused by a second mutation of the EGFR gene, leading to a T790M amino acid change in the EGFR...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Apoptosis
• Share to DNA-Binding Proteins